The authors thank Janet Ratziu for the proofreading of the English version letter.
Author contributions: AJ and SE wrote the paper, collected data and searched the literature. MD and LP performed the biological assays. SE, LG, FD, SM, JLW, and MCV examined the patients. SE and MCV supervised the work. All authors interpreted the data and contributed to the final version of the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Author disclosure statement: The authors have nothing to disclose concerning this study.
1. Garber J, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012;18:988–1028.10.4158/EP12280.GLSearch in Google Scholar
2. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2013;23:14–24.10.1089/thy.2012.0374Search in Google Scholar
3. Diana T, Krause J, Olivo PD, König J, Kanitz M, Decallonne B, et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 2017;189:304–9.10.1111/cei.12980Search in Google Scholar
5. Massart C, Orgiazzi J, Maugendre D. Clinical validity of a new commercial method for detection of TSH-receptor bindingantibodies in sera from patients with Graves’ disease treated with antithyroid drugs. Clin Chim Acta 2001;304:39–47.10.1016/S0009-8981(00)00385-5Search in Google Scholar
6. Takasu N, Yamada T, Takasu M, Komiya I, Nagasawa Y, Asawa T, et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 1992;326:513–8.10.1056/NEJM199202203260803Search in Google Scholar
7. Sato K, Okamura K, Yoshinari M, Ikenoue H, Kuroda T, Torisu M, et al. Goitrous hypothyroidism with blocking or stimulating thyrotropin binding inhibitor immunoglobulins. J Clin Endocrinol Metab 1990;71:855–60.10.1210/jcem-71-4-855Search in Google Scholar
8. Yoshida S, Takamatsu J, Kuma K, Ohsawa N. Thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies during the pregnancy and postpartum period: a case report. Thyroid 1992;2:27–30.10.1089/thy.1992.2.27Search in Google Scholar
9. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Jørgensen T, et al. Thyroid volume in hypothyroidism due to autoimmune disease follows a unimodal distribution: evidence against primary thyroid atrophy and autoimmune thyroiditis being distinct diseases. J Clin Endocrinol Metab 2009;94:833–9.10.1210/jc.2008-1370Search in Google Scholar
10. Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011;118:1693–8.10.1182/blood-2011-02-336156Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston